CAR T-cell Therapy Market by Product (Abecma, Breyanzi, Carvykti, Yescarta, Tecartus, Kymriah), Target Antigen (CD19, BCMA), Indication (Multiple Myeloma, Leukemia, Lymphoma), Demographic (Adult, Pediatric), End User & Region - Global Forecast to 2029
Market Growth Outlook Summary
The global CAR T-cell therapy market growth forecasted to transform from USD 5.5 billion in 2024 to USD 29.0 billion by 2029, driven by a CAGR of 39.6%. The growth of this market due to the rise in investments and funding for CAR T-cell therapy developments and technological advancements in CAR T-cell therapy. The growing prevalence of cancer is also expected to support lucrative market growth. However, the high costs of CAR T-cell therapies and the adverse effects of the drugs are some of the factors likely to hamper the market growth.
CAR T-cell Therapy Market Trends
To know about the assumptions considered for the study, Request for Free Sample Report
Global CAR T-cell therapy market Dynamics
Driver: Growing cancer prevalence
The growing prevalence of cancer is a prominent driver of market growth. According to the World Health Organization, in 2022, there were ~20 million new cancer cases and 9.7 million cancer-related deaths globally. An estimated 53.5 million individuals were living within five years of a cancer diagnosis. Statistically, about one-fifth of people will develop cancer in their lifetime, with approximately 1 in 9 men and 1 in 12 women succumbing to the disease. A projected surge of over 35 million new cancer cases is anticipated by 2050, reflecting a substantial 77% increase from the estimated 20 million cases recorded in 2022. Of these, Diffuse Large B-Cell Lymphoma (DLBCL) is the predominant form of Non-Hodgkin Lymphoma (NHL) in the US and globally, representing ~22% of newly identified cases of B-cell NHL in the US. Each year, over 18,000 individuals receive a diagnosis of DLBCL.
Restraint: High therapy costs
The high cost of CAR T-cell therapy represents a significant restraint on the market, posing challenges to widespread adoption and accessibility. One of the primary factors contributing to the elevated cost is the complex and individualized manufacturing process required for CAR T-cell therapies. Each treatment involves extracting T cells from the patient, genetically modifying them to express chimeric antigen receptors (CARs), and expanding these cells in a controlled laboratory environment before reinfusing them into the patient. This labor-intensive and time-consuming process incurs substantial costs, often exceeding USD 350,000 per treatment, as seen with therapies like KYMRIAH and Yescarta.
Opportunity: Expansion into solid tumors
Expansion into solid tumors represents a significant opportunity for the CAR T-cell therapy market, offering the potential for market growth and therapeutic advancements. Traditionally, CAR T-cell therapies have successfully treated hematologic malignancies such as B-cell lymphomas and Acute Lymphoblastic Leukemia (ALL). However, the application of CAR T-cell therapies to solid tumors has been limited due to unique challenges such as the hostile tumor microenvironment, heterogeneity, and physical barriers within solid tumors. Advances in this area can unlock new avenues for growth and innovation in the market.
Challenge: Patient recruitment for trials
Patient recruitment for clinical trials is a significant challenge in the CAR T-cell therapy market, posing obstacles to developing and approving new therapies. The complexity of CAR T-cell therapy trials, stringent eligibility criteria, and the rarity of target indications all contribute to the difficulty of enrolling sufficient patient numbers. One primary challenge is the stringent eligibility criteria for CAR T-cell trials. These criteria often include specific genetic markers, disease subtypes, and previous treatment histories, significantly narrowing the pool of eligible participants. Moreover, the geographic dispersion of patients with rare cancers adds complexity to patient recruitment. Rare conditions such as certain types of Acute Lymphoblastic Leukemia (ALL) or relapsed large B-cell Lymphoma have a limited patient base scattered across wide regions. This dispersion complicates the logistics of enrolling and managing patients in clinical trials.
Ecosystem Analysis Car T-Cell Therapy Manufacturing Market
The product CAR T-cell therapy segment of the Car T-Cell Therapy Manufacturing Industry commanded market share in 2023.
Based on the products, the CAR T-cell therapy market is segmented into Abecma (idecabtagene vicleucel), Breyanzi (lisocabtagene maraleucel), Carvykti (ciltacabtagene autoleucel), Yescarta (axicabtagene ciloleucel), Tecartus (brexucabtagene autoleucel), Kymriah (tisagenlecleucel) and other products. The Yescarta segment accounted for the largest share of the CAR T-cell therapy market in 2023. The high share of this segment is mainly attributed to the early entry into the market allowing Gilead Sciences, Inc. to gain significant experience in commercialization and market dynamics and establish a strong brand presence. Additionally, advancements in Yescarta is further likely to drive segmental growth. For example, Gilead Sciences, Inc. received U.S. FDA approval for a change in the manufacturing process for Yescarta which would result in reduced median turnaround time from leukapheresis to product release from 16 Days to 14 Days.
The CD19 target antigen segment of the CAR T-cell therapy industry is poised to exhibit substantial growth at a significant CAGR throughout the forecast period.
Based on targets, the CAR T-cell therapy market is classified into segmented into BCMA, CD19 and other targets. In 2023, the CD19 targets segment accounted for the highest share of the global CAR T-cell therapy market. The large share of this segment is due to the to the growing prevalence of cancers such as B-cell Lymphomas which express CD19 antigen on the cell surface.
Asia Pacific region of the CAR T-cell therapy industry is estimated to exhibit highest CAGR during the forecast period of 2024-2029.
There are five main regional segmentations for the CAR T-cell therapy market—North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. In 2023, North America held dominant share in CAR T-cell therapy market. Early adoption & regulatory framework, significant investment in research and development and advanced healthcare infrastructure are some of the factors uplifting the market growth in the region. Asia Pacific is anticipated to grow at significant CAGR during the forecast period of 2024-2029. Increasing healthcare investments, rising cancer incidence, rich CAR T-cell therapy pipeline development, and supportive regulatory frameworks are likely to drive the growth of the CAR T-cell therapy market in the region.
Source: Expert Interviews, Secondary Research, Whitepapers, Journals, Magazines, and MarketsandMarkets Analysis
To know about the assumptions considered for the study, download the pdf brochure
Key players in the Market include Bristol-Myers Squibb Company (US), Gilead Sciences, Inc. (US), Novartis AG (Switzerland), Johnson & Johnson (US), CARsgen Therapeutics Holdings Limited (China), IASO Biotherapeutics (China), JW (Cayman) Therapeutics Co. Ltd (China), ImmunoAct (India), CRISPR Therapeutics (Switzerland), Autolus Therapeutics (UK), Allogene Therapeutics (US), Cartesian Therapeutics, Inc. (US), Guangzhou Bio-gene Technology Co., Ltd (China) and Wugen (US).
Scope of the CAR T-cell Therapy Industry:
|
Report Metric |
Details |
|
Market Revenue in 2024 |
$5.5 billion |
|
Projected Revenue by 2029 |
$29.0 billion |
|
Revenue Rate |
Poised to Grow at a CAGR of 39.6% |
|
Market Driver |
Growing cancer prevalence |
|
Market Opportunity |
Expansion into solid tumors |
This report categorizes the CAR T-cell therapy market to forecast revenue and analyze trends in each of the following submarkets:
By Product
- ABECMA
- BREYANZI
- CARVYKTI
- YESCARTA
- TECARTUS
- KYMRIAH
- Other Products
By Target
- CD19
- BCMA
- Other Targets
By Indication
- Multiple Myeloma
- B-Cell Lymphoma (BCL)
- Acute Lymphoblastic Leukemia (ALL)
- Other Indications
By Demographic
- Adult
- Pediatric
By End User
- Hospitals
- Long Term Care Facilities
- Specialty Centres
By Region
-
North America
- US
- Canada
-
Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
-
Asia Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia Pacific
-
Latin America
- Brazil
- Rest of Latin America
- Middle East & Africa
Recent Developments of CAR T-cell Therapy Industry:
- In May 2024, The US FDA granted accelerated approval to BREYANZI (lisocabtagene maraleucel) for the treatment of adult patients with relapsed or refractory Follicular Lymphoma (FL) who have received two or more prior lines of systemic therapy.
- In April 2024, Bristol entered into a worldwide capacity reservation and supply agreement with Cellares to manufacture CAR T-cell therapies using Cellares’s automated & high-throughput manufacturing platform called Cell Shuttle.
- In January 2023, Gilead received approval from the US FDA for a change in manufacturing processes for YESCARTA (axicabtagene ciloleucel) to reduce the median turnaround time (TAT) in the US to 14 days from 16 days.
Frequently Asked Questions (FAQ):
What is the expected growth rate of the CAR T-cell therapy market between 2024 and 2029?
The global CAR T-cell therapy market is projected to grow from USD 5.5 billion in 2024 to USD 29.0 billion by 2029, demonstrating a robust CAGR of 39.6%.
What factors are driving the growth of the CAR T-cell therapy market?
The CAR T-cell therapy market is driven by the rising prevalence of cancer, increasing investments and funding in CAR T-cell therapy research, and the development of advanced CAR T-cell therapies.
What are the major challenges in the CAR T-cell therapy market?
Challenges in the CAR T-cell therapy market include high therapy costs and difficulties in patient recruitment for clinical trials, particularly for rare cancers and target indications.
Which product held the largest share of the CAR T-cell therapy market in 2023?
Yescarta (axicabtagene ciloleucel) accounted for the largest share of the CAR T-cell therapy market in 2023, driven by its early market entry and advancements in the manufacturing process that reduced turnaround times.
What is the key opportunity for the CAR T-cell therapy market?
The expansion of CAR T-cell therapies into solid tumors presents a significant opportunity for market growth, potentially unlocking new applications and driving therapeutic advancements in the field.
Which region is expected to exhibit the highest growth in the CAR T-cell therapy market?
The Asia Pacific region is projected to exhibit the highest CAGR during the forecast period of 2024–2029, driven by rising healthcare investments, increasing cancer incidence, and a growing CAR T-cell therapy pipeline.
How does the high cost of CAR T-cell therapy impact market adoption?
The high cost of CAR T-cell therapy, often exceeding USD 350,000 per treatment, limits its widespread adoption and accessibility, posing a significant challenge to market growth.
What are the key targets for CAR T-cell therapies?
The key targets for CAR T-cell therapies include BCMA and CD19, with the CD19 target segment holding the largest market share due to its association with cancers such as B-cell Lymphomas.
What is the role of technological advancements in the CAR T-cell therapy market?
Technological advancements in CAR T-cell therapy, such as improvements in the manufacturing process and developments in targeting solid tumors, are expected to significantly drive market growth and innovation.
What are the recent developments in the CAR T-cell therapy market?
Recent developments include the US FDA granting accelerated approval for BREYANZI for relapsed or refractory Follicular Lymphoma and Gilead Sciences' improvements in Yescarta's manufacturing process.
To speak to our analyst for a discussion on the above findings, click Speak to Analyst
Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.
This study involved four major activities in estimating the current size of the CAR T-cell therapy market. Exhaustive secondary research was carried out to collect information on the market, its peer markets, and its parent market. These findings, assumptions, and sizing were then validated with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. Following this, market breakdown and data triangulation procedures were used to estimate the market size of segments and subsegments.
Secondary Research
Secondary research was used mainly to identify and collect information for the extensive, technical, market-oriented, and commercial study. The secondary sources referred for this research study include publications from government sources, such as the National Center for Biotechnology Information (NCBI), National Institutes of Health (NIH), World Health Organization (WHO), United States Food and Drug Administration (US FDA), American Society of Gene & Cell Therapy (ASGCT), European Medicines Agency (EMA), Industry Association of Synthetic Biology (IASB), International Society for Cell & Gene Therapy (ISCT), National Center for Complementary and Integrative Health (NCCIH), BioPharm International, ScienceDirect, News Articles, Journals, Press Releases, Paid Databases, Expert Interviews, and MarketsandMarkets Analysis, among others. Secondary sources also included corporate and regulatory filings (such as annual reports, SEC filings, investor presentations, and financial statements); business magazines and research journals; press releases; and trade, business, and professional associations. These sources were also used to obtain key information about major players, global product revenues, market classification, and segmentation according to industry trends, regional/country-level markets, market developments, and technology perspectives. Secondary data was collected and analyzed to arrive at the overall size of the global CAR T-cell therapy market, which was validated through primary research.
Primary Research
In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among other experts, to obtain and verify the critical qualitative and quantitative information as well as assess future prospects of the market. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information. The following is a breakdown of the primary respondents:
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
The global size of the CAR T-cell therapy market was estimated through multiple approaches. A detailed market estimation approach was followed to estimate and validate the value of the market and other dependent submarkets. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
- The major players in the industry and market have been identified through extensive primary and secondary research.
- The CAR T-cell therapy-related business shares of leading players have been determined through secondary research and primary analysis.
- All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.
Market Size Estimation Methodology-Bottom-up approach
To know about the assumptions considered for the study, Request for Free Sample Report
Top-down Approach-
Data Triangulation
After estimating the overall market size from the market size estimation process, the total market was split into several segments. To complete the overall market engineering process and arrive at the exact statistics for all segments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.
Market Definition
CAR T-cell therapy is a treatment method wherein a patient's T-cells (a type of immune system cell) undergo modification in a laboratory to target and attack cancer cells effectively. Initially, T-cells are extracted from the patient's bloodstream. Then the gene for a special receptor that binds to a specific protein on the patient's cancer cells is added to the T cells in the laboratory. The special receptor is known as chimeric antigen receptor (CAR). Following this modification process, the CAR T-cells are cultured and multiplied in large quantities. Finally, the amplified CAR T-cells are administered to the patient via infusion. This therapeutic approach is predominantly utilized in the management of specific blood cancers, and ongoing research is exploring its potential applications in treating other forms of cancer. The CAR T-Cell therapy market includes approved and pipeline CAR T-cell products for therapy purpose.
Key Stakeholders
- Pharmaceutical Companies
- Biotechnology Companies
- Clinical Research Organizations (CROs)
- Regulatory Authorities
- Healthcare Providers
- Patients and Patient Advocacy Groups
- Investors and Venture Capital Firms
- Research & Development Companies
- Research Laboratories & Academic Institutes.
- Market Research & Consulting Firms
The main objectives of this study are as follows:
- To define, describe, and forecast the CAR T-cell therapy market by value for product, target, indication, demographic, end user, and region
- To define, describe, and forecast the CAR T-cell therapy market by volume for the product segment at global level.
- To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
- To analyze the micromarkets with respect to individual growth trends, prospects, and contributions to the overall CAR T-cell therapy market
- To analyze the opportunities for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of the market segments with respect to five regions: North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
- To profile the key players and analyze their market shares and core competencies
- To track and analyze competitive developments, such as product launches, partnerships, agreements, collaborations, and expansions.
- To benchmark players within the market using the proprietary “Company Evaluation Matrix” framework, which analyzes market players on various parameters within the broad categories of business and product excellence strategy.
- To provide an overview of the market with specialized analysis such as trends/distruptions impacting customers business, pricing analysis, value/ supply chain analysis, ecosystem analysis, technology analysis, patent analysis, key conferences & events 2024-2025, regulatory landscape, porter’s five forces’ analysis, key stakeholder and buying criteria, and investment and funding scenario
Available Customizations
With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for this report with additional efforts:
Product Information
- Country-wise Information: Analysis for additional countries (up to five)
- Company Information: Detailed analysis and profiling of additional key market players across the globe
Growth opportunities and latent adjacency in CAR T-cell Therapy Market